These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 30181337)

  • 1. T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection.
    Trujillo JA; Sweis RF; Bao R; Luke JJ
    Cancer Immunol Res; 2018 Sep; 6(9):990-1000. PubMed ID: 30181337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response.
    Garris CS; Luke JJ
    Clin Cancer Res; 2020 Aug; 26(15):3901-3907. PubMed ID: 32332013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment.
    Gajewski TF
    Semin Oncol; 2015 Aug; 42(4):663-71. PubMed ID: 26320069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment.
    Gajewski TF; Corrales L; Williams J; Horton B; Sivan A; Spranger S
    Adv Exp Med Biol; 2017; 1036():19-31. PubMed ID: 29275462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
    Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy of Pediatric Solid Tumors: Treatments at a Crossroads, with an Emphasis on Antibodies.
    Casey DL; Cheung NV
    Cancer Immunol Res; 2020 Feb; 8(2):161-166. PubMed ID: 32015013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment.
    Spranger S
    Int Immunol; 2016 Aug; 28(8):383-91. PubMed ID: 26989092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types.
    Bao R; Stapor D; Luke JJ
    Genome Med; 2020 Oct; 12(1):90. PubMed ID: 33106165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pushing Past the Blockade: Advancements in T Cell-Based Cancer Immunotherapies.
    Waibl Polania J; Lerner EC; Wilkinson DS; Hoyt-Miggelbrink A; Fecci PE
    Front Immunol; 2021; 12():777073. PubMed ID: 34868044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. WNT/β-Catenin Signaling Pathway Regulating T Cell-Inflammation in the Tumor Microenvironment.
    Li X; Xiang Y; Li F; Yin C; Li B; Ke X
    Front Immunol; 2019; 10():2293. PubMed ID: 31616443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy.
    Kumar A; Chamoto K; Chowdhury PS; Honjo T
    Elife; 2020 Mar; 9():. PubMed ID: 32122466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The T-cell-inflamed tumor microenvironment as a paradigm for immunotherapy drug development.
    Olson DJ; Luke JJ
    Immunotherapy; 2019 Feb; 11(3):155-159. PubMed ID: 30730272
    [No Abstract]   [Full Text] [Related]  

  • 13. Hijacked Immune Cells in the Tumor Microenvironment: Molecular Mechanisms of Immunosuppression and Cues to Improve T Cell-Based Immunotherapy of Solid Tumors.
    Balta E; Wabnitz GH; Samstag Y
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obstacles to T cell migration in the tumor microenvironment.
    Nicolas-Boluda A; Donnadieu E
    Comp Immunol Microbiol Infect Dis; 2019 Apr; 63():22-30. PubMed ID: 30961814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Turning tumors from cold to inflamed to improve immunotherapy response.
    Gerard CL; Delyon J; Wicky A; Homicsko K; Cuendet MA; Michielin O
    Cancer Treat Rev; 2021 Dec; 101():102227. PubMed ID: 34656019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunotherapy in cancer. Current prospects, challenges and new horizons].
    Dalotto-Moreno T; Blidner AG; Girotti MR; Maller SM; Rabinovich GA
    Medicina (B Aires); 2018; 78(5):336-348. PubMed ID: 30285926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostaglandin E Receptor 4 Antagonist in Cancer Immunotherapy: Mechanisms of Action.
    Take Y; Koizumi S; Nagahisa A
    Front Immunol; 2020; 11():324. PubMed ID: 32210957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma.
    Bao R; Spranger S; Hernandez K; Zha Y; Pytel P; Luke JJ; Gajewski TF; Volchenboum SL; Cohn SL; Desai AV
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34272305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment.
    Kawashima S; Inozume T; Kawazu M; Ueno T; Nagasaki J; Tanji E; Honobe A; Ohnuma T; Kawamura T; Umeda Y; Nakamura Y; Kawasaki T; Kiniwa Y; Yamasaki O; Fukushima S; Ikehara Y; Mano H; Suzuki Y; Nishikawa H; Matsue H; Togashi Y
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34795004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer immunoediting and resistance to T cell-based immunotherapy.
    O'Donnell JS; Teng MWL; Smyth MJ
    Nat Rev Clin Oncol; 2019 Mar; 16(3):151-167. PubMed ID: 30523282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.